1975
DOI: 10.1016/0014-4886(75)90140-5
|View full text |Cite
|
Sign up to set email alerts
|

Histochemical changes in innervated and denervated skeletal muscle fibers following treatment with bupivacaine (marcain)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
18
0

Year Published

1977
1977
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(20 citation statements)
references
References 14 publications
2
18
0
Order By: Relevance
“…On muscle cross-sections, newly formed myofibers can be readily distinguished by their small caliber and centrally located myonuclei. These myofibers are often basophilic in the beginning of regeneration due to protein synthesis and the expression of embryonic/developmental forms of MyHC (217,562). On muscle longitudinal sections and on isolated single myofibers, the centrally localized myonuclei were observed in discrete segments of regenerating myofibers or along the entire new myofiber, which suggests that cell fusion during regeneration happens in a focal, rather than diffuse, manner (58).…”
Section: /Cd163mentioning
confidence: 99%
“…On muscle cross-sections, newly formed myofibers can be readily distinguished by their small caliber and centrally located myonuclei. These myofibers are often basophilic in the beginning of regeneration due to protein synthesis and the expression of embryonic/developmental forms of MyHC (217,562). On muscle longitudinal sections and on isolated single myofibers, the centrally localized myonuclei were observed in discrete segments of regenerating myofibers or along the entire new myofiber, which suggests that cell fusion during regeneration happens in a focal, rather than diffuse, manner (58).…”
Section: /Cd163mentioning
confidence: 99%
“…Local anesthetics, usually used to reversibly block nerve conduction, may also affect a variety of non-neuronal processes: excitation-contraction coupling in muscles (Bianchi and Bolton 1967;Suko et al 1976;NashAdler et al 1980;Wolosker et al 1992), uncoupling of mitochondrial oxidative phosphorylation (Moseley and Sisso 1972;Dabadie et al 1987;Sztark et al 1997), inhibition of Ca 2+ -calmodulin-dependent enzymes (Tanaka and Hidaka 1981;Volpi et al 1981), inhibition of histamine release from mast cells (Kazimierczak et al 1976), inhibition of Ca 2+ -Mg 2+ -ATPase activity in brain synaptosomes (García-Martín and Gutiérrez-Merino 1986), increase in the membrane permeability to Ca 2+ and Mg 2+ (Low et al 1979;Escudero and Gutiérrez-Merino 1987); they also promote histochemical changes in skeletal muscle (Hall-Craggs 1974;Hall-Craggs and Seyan 1975) and cause injuries in corneal epithelia (Grant and Acosta 1994), among other effects (Ohki 1984;Ragsdale et al 1994;Takahashi 1994;Fujita et al 1998).…”
Section: Introductionmentioning
confidence: 94%
“…Other authors (Sokoll et al, 1968;Benoit & Belt, 1970;Libelius, Sonesson, Stamenovic & Theslef, 1970) have reported degeneration in the superficial parts of muscles when the same dose was administered into the subcutaneous space. In these cases the intramuscular concentration is not derivable but probably would have been lower than the level of 1 mg cm-3 that resulted from direct intramuscular injection (Hall-Craggs & Singh Seyan, 1975). It can be concluded therefore that provided the maximum permitted dose is not exceeded, bupivacaine probably does not cause muscle degeneration when used as a regional intravenous anaesthetic.…”
Section: Discussionmentioning
confidence: 97%
“…The dose of 150mg bupivacaine was therefore distributed in the soft tissues at a concentration of 0.8 mg cm-3 which was far lower than the level of 3 mg cm-3 in the rat calf muscles (mean volume in 10 animals was 5 cm3). However, local degeneration has been demonstrated histologically in the soleus muscle following the intramuscular injection of only 2.5 mg bupivacaine (Hall-Craggs & Singh Seyan, 1975) which would have resulted in a muscle concentration of approximately 1 mg cm-3. Other authors (Sokoll et al, 1968;Benoit & Belt, 1970;Libelius, Sonesson, Stamenovic & Theslef, 1970) have reported degeneration in the superficial parts of muscles when the same dose was administered into the subcutaneous space.…”
Section: Discussionmentioning
confidence: 99%